{"id":"https://genegraph.clinicalgenome.org/r/218b7e0c-d9c4-4835-920b-ba3d24173c5ev1.0","type":"EvidenceStrengthAssertion","dc:description":"FUS was first reported in relation to autosomal dominant amyotrophic lateral sclerosis 6 (ALS) in 2009 (Kwiatkowski TJ, et al., 2009, PMID: 19251627 and Vance C, et al., 2009, PMID: 19251628). ALS is a neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. FUS encodes a nucleoprotein that functions in DNA and RNA metabolism, including DNA repair, and the regulation of transcription, RNA splicing, and export to the cytoplasm. It’s proposed that the FALS-associated FUS mutations alter the liquid-solid phase transition in FUS and thereby dominantly interfere with the ability of wild type FUS in DNA damage repair and RNA splicing, leading to both structural and functional defects in dendritic/axonal growth and synaptic transmission (PMID: 27033831). Evidence supporting this gene-disease relationship includes case-level data and experimental data. More than 50 mutations in FUS have been associated with ALS, the majority of which are dominant, missense changes clustered in and around the C-terminal nuclear localization signal, as well as some nonsense, splicing, and frameshift variants (reviewed in PMID: 27033831). This curation includes 26 variants in this gene that have been reported in 26 probands in 7 publications (PMIDs: 19251627, 19251628, 19741215, 20232451, 26362943, 22057404, and 20668259). Experimentally, this gene-disease relationship is supported the alterations observed in cells expressing FUS variants, showing mislocalization to the cytoplasm and association with stress granules (PMID: 23474818) as well as decreased DNA repair (PMID: 24036913). Further support is provided by several animal models (at least 6 transgenic strains, reviewed in PMID: 27033831) including mouse (PMID: 26842965) and rat models (PMID: 21408206), which recapitulate features of ALS. In summary FUS is definitively associated with autosomal dominant amyotrophic lateral sclerosis 6. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen ALS GCEP on 10/12/2021 (SOPv8).\nOf note, FUS has also been reported in relation to autosomal dominant hereditary essential tremor 4. This will be curated separately from ALS per criteria outlined by the ClinGen Lumping and Splitting working group; there is a difference in molecular mechanism (gain of toxicity vs loss of function) and phenotype.","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/218b7e0c-d9c4-4835-920b-ba3d24173c5e","GCISnapshot":"https://genegraph.clinicalgenome.org/r/b2e8f55b-371e-438f-8923-73ca9b7ec034","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/b2e8f55b-371e-438f-8923-73ca9b7ec034_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10096","date":"2021-10-12T18:36:10.096Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/b2e8f55b-371e-438f-8923-73ca9b7ec034_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10096","date":"2021-10-12T18:36:01.087Z","role":"Approver"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b2e8f55b-371e-438f-8923-73ca9b7ec034_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cff0de3f-853f-4bde-9eb9-9d23a7215ad5","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cff0de3f-853f-4bde-9eb9-9d23a7215ad5_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"From PMID: 21725888, R522G expressed in SH-SY5Y predominantly accumulated in the cytoplasm and formed aggregates.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/cff0de3f-853f-4bde-9eb9-9d23a7215ad5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19251627","allele":{"id":"https://genegraph.clinicalgenome.org/r/248b0022-c5d6-47cc-957b-bc28819f80c1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004960.3(FUS):c.1564A>G (p.Arg522Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA395677460"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/b2e8f55b-371e-438f-8923-73ca9b7ec034_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0dba4fe4-1107-4c55-8c46-a101197dc329_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19251628","rdfs:label":"F1015","estimatedLodScore":0.9,"family":{"id":"https://genegraph.clinicalgenome.org/r/0dba4fe4-1107-4c55-8c46-a101197dc329","type":"Family","rdfs:label":"F1015","member":{"id":"https://genegraph.clinicalgenome.org/r/5a445307-f898-4b7d-984b-70425c03d89f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19251628","rdfs:label":"F1015 III:1","allele":{"id":"https://genegraph.clinicalgenome.org/r/ae777a1b-78e4-41e4-83ad-f55edbaf777a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004960.3(FUS):c.1562G>A (p.Arg521His)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA257443"}},"firstTestingMethod":"Sanger sequencing","phenotypes":"obo:HP_0007354","previousTestingDescription":"SOD1, VAPB, ANG, Dynactin, CHMP2B, and TARDBP mutations had been excluded","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/01481afc-8da2-4db0-b7d6-02570bb05df7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19251628","allele":{"id":"https://genegraph.clinicalgenome.org/r/ae777a1b-78e4-41e4-83ad-f55edbaf777a"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":4,"phenotypes":"obo:HP_0007354","proband":{"id":"https://genegraph.clinicalgenome.org/r/5a445307-f898-4b7d-984b-70425c03d89f"}},{"id":"https://genegraph.clinicalgenome.org/r/212a2ecb-0f9a-4846-9eea-047e13260214_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19251628","rdfs:label":"F1","estimatedLodScore":2.71,"family":{"id":"https://genegraph.clinicalgenome.org/r/212a2ecb-0f9a-4846-9eea-047e13260214","type":"Family","rdfs:label":"F1","member":{"id":"https://genegraph.clinicalgenome.org/r/85c8c6f3-6bf4-4788-a0b1-03082153c14f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19251628","rdfs:label":"IV:1","allele":{"id":"https://genegraph.clinicalgenome.org/r/9dcf0034-abbd-4b99-a84e-7763572d7df6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004960.3(FUS):c.1561C>T (p.Arg521Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA257441"}},"detectionMethod":"Following linkage analyses, used a candidate gene approach, sequencing 279 exons from 32 genes and expressed sequence tags (ESTs) and 10 noncoding RNAs. ","firstTestingMethod":"Linkage analysis","phenotypeFreeText":"limb onset","phenotypes":"obo:HP_0007354","previousTestingDescription":"No mutations detected in SOD1 and linkage to ALS loci was excluded for 18q21 and 9q21.","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/6c21da0d-5663-4953-b749-5942ca91bd22_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19251628","allele":{"id":"https://genegraph.clinicalgenome.org/r/9dcf0034-abbd-4b99-a84e-7763572d7df6"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"limb onset, mean age at onset was 38 years (range 29–51 years), and mean survival was 13 mo (range 7–27 mo)","phenotypePositiveAllelePositive":6,"phenotypes":"obo:HP_0007354","proband":{"id":"https://genegraph.clinicalgenome.org/r/85c8c6f3-6bf4-4788-a0b1-03082153c14f"},"publishedLodScore":3.85,"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/d652bcdb-33ea-4f77-be30-b39461e3305f_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20668259","rdfs:label":"F476","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/d652bcdb-33ea-4f77-be30-b39461e3305f","type":"Family","rdfs:label":"F476","member":{"id":"https://genegraph.clinicalgenome.org/r/f0099386-0ea9-41eb-9377-8e0a7962ea46","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20668259","rdfs:label":"III:1","allele":{"id":"https://genegraph.clinicalgenome.org/r/a03c42ce-a6d9-49a9-9945-daafcc6a36bd","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004960.4(FUS):c.1562G>T (p.Arg521Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/873232"}},"detectionMethod":"sequencing covered the coding sequence","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"ALS was diagnosed according to the El Escorial criteria","phenotypes":"obo:HP_0007354","previousTestingDescription":"Negative for mutations in SOD1 and TARDBP.","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/e85e08fb-9f69-4b25-8f04-a4392d543b77_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20668259","allele":{"id":"https://genegraph.clinicalgenome.org/r/a03c42ce-a6d9-49a9-9945-daafcc6a36bd"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":3,"phenotypes":"obo:HP_0007354","proband":{"id":"https://genegraph.clinicalgenome.org/r/f0099386-0ea9-41eb-9377-8e0a7962ea46"}},{"id":"https://genegraph.clinicalgenome.org/r/bf575232-4655-4e98-a5cd-52771505702a_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19251628","rdfs:label":"F1083","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/bf575232-4655-4e98-a5cd-52771505702a","type":"Family","rdfs:label":"F1083","member":{"id":"https://genegraph.clinicalgenome.org/r/5ceacd46-a2bc-4d46-8eee-8822027b687e","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19251628","rdfs:label":"III:1","allele":{"id":"https://genegraph.clinicalgenome.org/r/13666f8f-bdd6-4be2-a4d2-9425047000a3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004960.4(FUS):c.1540A>G (p.Arg514Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA395676122"}},"firstTestingMethod":"Sanger sequencing","phenotypes":"obo:HP_0007354","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/37a2f420-0473-4e9c-b0ad-27377437cab8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19251628","allele":{"id":"https://genegraph.clinicalgenome.org/r/13666f8f-bdd6-4be2-a4d2-9425047000a3"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":2,"phenotypes":"obo:HP_0007354","proband":{"id":"https://genegraph.clinicalgenome.org/r/5ceacd46-a2bc-4d46-8eee-8822027b687e"}},{"id":"https://genegraph.clinicalgenome.org/r/160e048a-4209-4853-a829-407c23e6fbf9_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20668259","rdfs:label":"F1186","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/160e048a-4209-4853-a829-407c23e6fbf9","type":"Family","rdfs:label":"F1186","member":{"id":"https://genegraph.clinicalgenome.org/r/f2eaf0ba-0c0f-4942-a428-2949b93a8d9d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20668259","rdfs:label":"II-1","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":44,"allele":{"id":"https://genegraph.clinicalgenome.org/r/d1e4cbec-6fb7-4e6a-8a1f-025673ac7264","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004960.3(FUS):c.1483C>T (p.Arg495Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA259631"}},"detectionMethod":"sequencing covered the coding sequence","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"ALS was diagnosed according to the El Escorial criteria, bulbar onset, disease duration 20 months","phenotypes":"obo:HP_0007354","previousTestingDescription":"Negative for mutations in SOD1 and TARDBP.","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/23c60391-cb19-4f34-a56d-aae81c763048_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20668259","allele":{"id":"https://genegraph.clinicalgenome.org/r/d1e4cbec-6fb7-4e6a-8a1f-025673ac7264"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":3,"phenotypes":"obo:HP_0007354","proband":{"id":"https://genegraph.clinicalgenome.org/r/f2eaf0ba-0c0f-4942-a428-2949b93a8d9d"}},{"id":"https://genegraph.clinicalgenome.org/r/99fa3c74-bacc-4818-b6d6-ad76b4d2ad71_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19251627","rdfs:label":"NUFMS9900","estimatedLodScore":2.71,"family":{"id":"https://genegraph.clinicalgenome.org/r/99fa3c74-bacc-4818-b6d6-ad76b4d2ad71","type":"Family","rdfs:label":"NUFMS9900","member":{"id":"https://genegraph.clinicalgenome.org/r/9d323569-c7e1-4830-9dd9-939e32faef7f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19251627","rdfs:label":"NUFMS9900 proband","allele":{"id":"https://genegraph.clinicalgenome.org/r/e152ac86-103c-47b1-8359-eaaa356a1de5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004960.3(FUS):c.1553G>A (p.Arg518Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA257439"}},"detectionMethod":"Sequenced all 15 exons of FUS.","firstTestingMethod":"Sanger sequencing","phenotypes":"obo:HP_0007354","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/4f8b1885-0873-4999-9dd1-12e483caed35_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19251627","allele":{"id":"https://genegraph.clinicalgenome.org/r/e152ac86-103c-47b1-8359-eaaa356a1de5"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"onset 40.3 +/- 6.6 years, duration 26.7 +/- months","phenotypePositiveAllelePositive":10,"phenotypes":"obo:HP_0007354","proband":{"id":"https://genegraph.clinicalgenome.org/r/9d323569-c7e1-4830-9dd9-939e32faef7f"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/77c8ac7f-3448-4abb-b6ef-9d028155b687_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19251627","rdfs:label":"F55","estimatedLodScore":1.2,"family":{"id":"https://genegraph.clinicalgenome.org/r/77c8ac7f-3448-4abb-b6ef-9d028155b687","type":"Family","rdfs:label":"F55","member":{"id":"https://genegraph.clinicalgenome.org/r/d2f77df3-9d4a-40d8-a5cf-923395d563be","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19251627","rdfs:label":"F55 Proband","allele":{"id":"https://genegraph.clinicalgenome.org/r/fac518c2-f99f-4b2b-a93d-dfbcade0a643","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004960.3(FUS):c.1561C>G (p.Arg521Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA257437"}},"detectionMethod":"sequenced all 15 exons of FUS","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0007354","obo:HP_0002398"],"sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/d37c00a7-5b73-40e9-8de6-fb758acefae1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19251627","allele":{"id":"https://genegraph.clinicalgenome.org/r/fac518c2-f99f-4b2b-a93d-dfbcade0a643"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"age of onset 39.6 +/- 13.3 years, duration 26.6 +/- 16.5 months","phenotypePositiveAllelePositive":5,"phenotypes":"obo:HP_0007354","proband":{"id":"https://genegraph.clinicalgenome.org/r/d2f77df3-9d4a-40d8-a5cf-923395d563be"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/ebad8eab-187f-40f9-a995-1b2ff4edaefb","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ebad8eab-187f-40f9-a995-1b2ff4edaefb_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In PMID: 24280224, G156E significantly increases the propensities for aggregation of FUS in vitro with formation of amyloid-like fibrillar aggregates observed in mutant but not wild-type FUS, and notably, those fibrils functioned as efficient seeds to trigger the aggregation of wild-type protein.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/ebad8eab-187f-40f9-a995-1b2ff4edaefb_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19741215","allele":{"id":"https://genegraph.clinicalgenome.org/r/4d6ba38e-6b00-422f-9830-ad7ccee761b5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004960.4(FUS):c.467G>A (p.Gly156Glu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA395668925"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/1d776ad4-e3b1-4127-9ab2-95fd3b1d3c5f","type":"EvidenceLine","dc:description":"The frameshift occurs in the final exon so is not expected to result in NMD but a truncated protein. LOF is not a known mechanism of disease for FUS associated ALS.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1d776ad4-e3b1-4127-9ab2-95fd3b1d3c5f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26362943","allele":{"id":"https://genegraph.clinicalgenome.org/r/47933dc9-1cd2-4abd-a6e8-57483f1c05e9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004960.3(FUS):c.1504del (p.Asp502fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA658798600"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/47061286-0542-4909-88be-ae5d1fbcced6","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/47061286-0542-4909-88be-ae5d1fbcced6_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"FLAG tagged R514S-FUS transfected in NSC-34 cells showed cytoplasmic mislocalization (17.3 ± 1.5%) and formed nuclear aggregates.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/47061286-0542-4909-88be-ae5d1fbcced6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22057404","allele":{"id":"https://genegraph.clinicalgenome.org/r/f525eeaa-5baf-4be4-921e-2cef79d3c3fa","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004960.4(FUS):c.1542G>C (p.Arg514Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA395677219"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/6b59eebb-2802-423f-8021-5079269f7172","type":"EvidenceLine","dc:description":"The frameshift occurs in the penultimate exon with a premature stop codon in the final exon so is not expected to result in NMD but a truncated protein. LOF is not a known mechanism of disease for FUS associated ALS.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6b59eebb-2802-423f-8021-5079269f7172_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26362943","allele":{"id":"https://genegraph.clinicalgenome.org/r/4a29bfce-71ff-47e0-b7a5-738f27be6b28","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004960.4(FUS):c.1484del (p.Arg495GlnfsTer34)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2497030155"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/e2b1f7b9-fa1f-4c7d-930e-8cab30c53c4e","type":"EvidenceLine","dc:description":"A LOF function mechanism has not been established for FUS associated ALS. This c.1394-2A>G variant, like the previously identified missense variants, was shown to affect protein localization.","calculatedScore":2.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e2b1f7b9-fa1f-4c7d-930e-8cab30c53c4e_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"cDNA analysis confirmed skipping of exon 14 resulting in a frameshift with a premature termination codon in exon 15 leading to a truncated FUS protein (p.G466VfsX14). Transient transfection of V5-FUSWT and V5-FUSΔ14 in N2A cells showed a predominant nuclear localization of V5-FUSWT in all transfected cells, while mutant V5-FUSΔ14 generally showed dense cytoplasmic fluorescent signal with a correspondingly dramatic loss of detection in the nucleus.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/e2b1f7b9-fa1f-4c7d-930e-8cab30c53c4e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20232451","allele":{"id":"https://genegraph.clinicalgenome.org/r/53a7a0aa-c235-43e9-81bb-25bbb89b3e9b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000016.10:g.31190961A>G (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA395675615"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/f7b41a74-72d6-4d54-a090-ac136e948928","type":"EvidenceLine","dc:description":"Present in the gnomADv2.1.1 non-neuro European population at a MAF of 0.00002412 (2/82926 alleles).","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f7b41a74-72d6-4d54-a090-ac136e948928_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19741215","allele":{"id":"https://genegraph.clinicalgenome.org/r/9e1c8d6c-a1fb-42e8-a7bf-19b795bb49ae","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004960.4(FUS):c.701G>T (p.Arg234Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA8023770"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/23c60391-cb19-4f34-a56d-aae81c763048","type":"EvidenceLine","dc:description":"The nonsense variant occurs in exon 14 of 15 and is predicted to cause NMD. LOF is not a known mechanism of disease for FUS associated ALS.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/23c60391-cb19-4f34-a56d-aae81c763048_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/6c21da0d-5663-4953-b749-5942ca91bd22","type":"EvidenceLine","dc:description":"This variant is present in the gnomADv2.1.1 non-neuro African/African American population at a MAF of 0.0003083 (1/3244 alleles). It has also been observed in additional FALS cases including four families in this publication and F072, F080 and F085 of PMID: 19251627.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6c21da0d-5663-4953-b749-5942ca91bd22_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"R521C FUS was transiently expressed in CV-1 and N2A cell lines and rat cortical neurons. Transfected cells show an increase in cytoplasmic localization of the FUSR521C protein when compared to the wild type, both with immunofluorescent labeling and by immunoblot.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/6c21da0d-5663-4953-b749-5942ca91bd22_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/39bbee09-af2a-434d-9a8b-cefa40ee1065","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/39bbee09-af2a-434d-9a8b-cefa40ee1065_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19251627","allele":{"id":"https://genegraph.clinicalgenome.org/r/6823f474-a828-4127-b25a-cbb2ceeabfb9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004960.4(FUS):c.1571G>C (p.Arg524Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA395677532"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/94df698f-ce95-4acb-b593-6db2691204d2","type":"EvidenceLine","dc:description":"This variant has been reported multiple times, including three de novo cases in this publication and F568 of PMID: 19251627.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/94df698f-ce95-4acb-b593-6db2691204d2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26362943","allele":{"id":"https://genegraph.clinicalgenome.org/r/352b6cad-e7bf-45cd-bd4b-66bb6d00b3f7","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004960.3(FUS):c.1574C>T (p.Pro525Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10603390"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/01481afc-8da2-4db0-b7d6-02570bb05df7","type":"EvidenceLine","dc:description":"This variant has been reported in several additional cases including family ALS156 and one index case in this publication as well as F067 in PMID: 19251627. This variant is present in the gnomADv2.1.1 non-neuro European population at a MAF of \t0.00001117 (1/89524 alleles).","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/01481afc-8da2-4db0-b7d6-02570bb05df7_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"R521H FUS was transiently expressed in CV-1 and N2A cell lines and rat cortical neurons. Transfected cells show an increase in cytoplasmic localization of the FUSR521H protein when compared to the wild type, both with immunofluorescent labeling and by immunoblot.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/01481afc-8da2-4db0-b7d6-02570bb05df7_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/22df33ec-c903-4dce-9624-6d85cf9202b2","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/22df33ec-c903-4dce-9624-6d85cf9202b2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19251627","allele":{"id":"https://genegraph.clinicalgenome.org/r/23659e30-38f9-4032-bf6e-25d77ec55ae0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004960.4(FUS):c.1542_1543delinsTT (p.Arg514_Gly515delinsSerCys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2497030131"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/e85e08fb-9f69-4b25-8f04-a4392d543b77","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e85e08fb-9f69-4b25-8f04-a4392d543b77_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/21ab4b96-cf14-4883-80f3-a9632d3ffd2c","type":"EvidenceLine","dc:description":"The frameshift occurs in the penultimate exon with a stop codon in the final exon so is not expected to result in NMD but a truncated protein. LOF is not a known mechanism of disease for FUS associated ALS.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/21ab4b96-cf14-4883-80f3-a9632d3ffd2c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20668259","allele":{"id":"https://genegraph.clinicalgenome.org/r/ab824243-55fa-485f-b329-207ae8b38eca","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004960.4(FUS):c.1483del (p.Arg495GlufsTer34)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2497030166"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/73686b25-a6c6-4e43-9898-5e1256ef0490","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/73686b25-a6c6-4e43-9898-5e1256ef0490_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19251627","allele":{"id":"https://genegraph.clinicalgenome.org/r/6a57f4f1-65ed-4a31-ac20-d4fef5c178ae","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004960.3(FUS):c.1572G>C (p.Arg524Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10603322"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/2a90e542-7665-4338-9b62-455b3d6e0b6b","type":"EvidenceLine","dc:description":"The frameshift occurs in the final exon so is not expected to result in NMD but a truncated protein. LOF is not a known mechanism of disease for FUS associated ALS.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2a90e542-7665-4338-9b62-455b3d6e0b6b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20668259","allele":{"id":"https://genegraph.clinicalgenome.org/r/62f128c1-1090-4e87-909c-6e020914c9d1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004960.4(FUS):c.1524_1527dup (p.Lys510TrpfsTer8)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2497030165"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/d37c00a7-5b73-40e9-8de6-fb758acefae1","type":"EvidenceLine","dc:description":"This variant has been reported in multiple additional FALS cases, including F002 and F136 from this publication.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d37c00a7-5b73-40e9-8de6-fb758acefae1_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Analyzed the subcellular distribution of WT compared to mutant R521G FUS after transient transfection in N2A and SKNAS cells. In contrast to WT, R521G showed dense cytoplasmic staining. Additionally, there was a higher ratio of insoluble to soluble protein.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/d37c00a7-5b73-40e9-8de6-fb758acefae1_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/40dfe3f6-73d9-402a-a81e-053f337195e0","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/40dfe3f6-73d9-402a-a81e-053f337195e0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19251627","allele":{"id":"https://genegraph.clinicalgenome.org/r/5e139112-d647-4ba7-a5ea-970ddc890af0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004960.4(FUS):c.730C>T (p.Arg244Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA395670416"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/4f8b1885-0873-4999-9dd1-12e483caed35","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4f8b1885-0873-4999-9dd1-12e483caed35_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/37a2f420-0473-4e9c-b0ad-27377437cab8","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/37a2f420-0473-4e9c-b0ad-27377437cab8_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In PMID: 23474818, CV-1 cells transfected with GFP-FUS-R514G there was increased cytoplasmic localization.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/37a2f420-0473-4e9c-b0ad-27377437cab8_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/bae5bdc1-5cac-40d9-9e8f-c275ecc3bdf6","type":"EvidenceLine","dc:description":"The frameshift occurs in the penultimate exon with a premature stop codon in the final exon so is not expected to result in NMD but a truncated protein. LOF is not a known mechanism of disease for FUS associated ALS.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bae5bdc1-5cac-40d9-9e8f-c275ecc3bdf6_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"FLAG tagged G492Efs-FUS transfected in NSC-34 cells showed significant cytoplasmic mislocalization (89.8 ± 2.3%, P < 0.05) and formed nuclear aggregates.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/bae5bdc1-5cac-40d9-9e8f-c275ecc3bdf6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22057404","allele":{"id":"https://genegraph.clinicalgenome.org/r/d0263553-1e8a-4c6d-8bf4-2cafdf974268","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004960.4(FUS):c.1475del (p.Gly492GlufsTer37)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2497030156"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/3814192b-a5fe-49d6-b94c-afe265521785","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3814192b-a5fe-49d6-b94c-afe265521785_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20668259","allele":{"id":"https://genegraph.clinicalgenome.org/r/b58ef737-50b8-442a-a09f-2714df925268","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004960.4(FUS):c.287_291delinsAT (p.Ser96del)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2497030167"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/73fdc75c-34ea-4863-bd65-f9d59f865f24","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/73fdc75c-34ea-4863-bd65-f9d59f865f24_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20232451","allele":{"id":"https://genegraph.clinicalgenome.org/r/644fb497-4e95-4fea-ab3f-639d7106ea12","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004960.4(FUS):c.1204_1232delinsGGAGGTGGAGG (p.Ser402_Pro411delinsGlyGlyGlyGly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2497030154"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/a30a8824-aa22-4b82-abb1-20a4225d7251","type":"EvidenceLine","dc:description":"The frameshift variant occurs in exon 14 of 15 with a premature stop codon in the final exon and is not predicted to cause NMD. LOF is not a known mechanism of disease for FUS associated ALS.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a30a8824-aa22-4b82-abb1-20a4225d7251_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20668259","allele":{"id":"https://genegraph.clinicalgenome.org/r/c6ec7796-30f2-4db4-8123-2ac3618dd968","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004960.4(FUS):c.1449_1488del (p.Tyr484AlafsTer32)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2497030169"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/5e4943b1-0c72-4f5d-acfc-2e9ea612b9fc","type":"EvidenceLine","dc:description":"The frameshift occurs in the penultimate exon with a premature stop codon in the final exon so is not expected to result in NMD but a truncated protein. LOF is not a known mechanism of disease for FUS associated ALS.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5e4943b1-0c72-4f5d-acfc-2e9ea612b9fc_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20668259","allele":{"id":"https://genegraph.clinicalgenome.org/r/f35233d8-2c88-4f71-a84e-7a97086b8c32","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004960.4(FUS):c.1485del (p.Gly497AlafsTer32)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2497030164"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/b2e8f55b-371e-438f-8923-73ca9b7ec034_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b2e8f55b-371e-438f-8923-73ca9b7ec034_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/89be54f5-96b8-4cd1-b543-31a8c73b8cd9","type":"EvidenceLine","dc:description":"Transgenic rats expressing the the R521C variant (identified in multiple unrelated ALS patients) had strong recapitulation of the human ALS phenotype.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6ff69fe9-39b6-45eb-a9c8-8a6f1f9a5e27","type":"Finding","dc:description":"Overexpression of a mutant (R521C substitution), but not normal, human FUS induced progressive paralysis resembling ALS. Mutant FUS transgenic rats developed progressive paralysis secondary to degeneration of motor axons, denervation atrophy of skeletal muscles, and displayed a substantial loss of neurons in the cortex and hippocampus.  Neuronal loss was accompanied by ubiquitin aggregation and glial reaction. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21408206","rdfs:label":"R521C transgenic rat","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/b6732544-b268-4ccf-992c-f332aa05fbc3","type":"EvidenceLine","dc:description":"Demonstrated that expression of mutant hFUS (R521C or P525L) is sufficient to cause MN degeneration, and that alleles associated with aggressive, juvenile-onset forms of ALS (P525L) are more pathogenic in these disease models.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/476bbbd4-af0c-4849-85e7-bcac6b955639","type":"Finding","dc:description":"As in patients, mutant FUS was found mislocalized to the cytoplasm, modelling a pathological hallmark of ALS-FUS. Analysis of these mutants (R521C and P525L) reveals progressive, age- and mutation-dependent motor neuron (MN) degeneration that faithfully models several key aspects of the ALS phenotype, including selectivity for MN subtypes most vulnerable in the human disease.  MN loss progressed steadily in both mutants to p360, but was more pronounced in the P525L mutant (∼30%), compared with the R521C mice (∼20%). MN loss in this model is associated with early synaptic failure and withdrawal of the motor axon from the neuromuscular junction. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26842965","rdfs:label":"Conditional transgenic mice","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/b2e8f55b-371e-438f-8923-73ca9b7ec034_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f8b0decb-bae8-4073-9111-bd239866f674","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/76ce6b51-62e0-42e7-804b-5aa74cf0665f","type":"FunctionalAlteration","dc:description":"The authors found that FUS mutant fibroblasts have significantly greater levels of cytoplasmic FUS than control fibroblasts under basal culture conditions and stress granules (as measured by PABP granule formation) were almost absent from mutant and control fibroblasts under these conditions. Following treatment with 1 mm arsenite, the mean number of stress granules per cell was significantly increased in both mutant and control fibroblasts compared with untreated cells but a striking difference in the distribution of FUS was observed only in mutant fibroblasts treated with arsenite, as cytoplasmic FUS was recruited to stress granules. The mean number of FUS-positive cytoplasmic granules per cell was significantly increased following arsenite treatment only in mutant fibroblasts [ANOVA, with a Greenhouse-Geisser correction, P < 0.001, Dunnett's T3 post-hoc tests for FUSR521C (P < 0.01) and FUSR514G (P < 0.01)]. These experiments demonstrate that endogenous levels of cytoplasmic FUS are increased in mutant fibroblasts compared with controls, and that only the cytoplasmic pool of FUS is recruited into stress granules following oxidative stress.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23474818","rdfs:label":"Stress granules"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/3ccb0eb9-3a5c-44b2-b1b8-075987f388fc","type":"EvidenceLine","dc:description":"The fundamental effects of mutant FUS proteins can be attributed to its aberrant gain-of-function properties that alter the homeostasis of the interactions of wild type FUS and its the interacting partners, including proteins, pre-mRNAs and lncRNAs, in the DNA damage response/repair and RNA splicing machinery..","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6ccc83e4-590a-4949-a040-aa56db585faf","type":"FunctionalAlteration","dc:description":"C-terminal ALS FUS mutants form cytoplasmic inclusions due to the disruption of the nuclear localization signal. In transiently transfected CV-1 cells, the GFP-FUSWT protein was predominantly nuclear, while the ALS mutants (GFP-FUSR521C, GFP-FUSR521H and GFP-FUSR514G) showed increased cytoplasmic localization in a high percentage of cells. The truncated FUS protein GFP-FUSK510X showed almost exclusive cytoplasmic localization, confirming that the C-terminal region contains the dominant NLS for FUS. This effect can be abolished by the addition of a wild-type NLS to mutant proteins; following the addition of the wild-type NLS to the wild-type protein FUS remained in the nucleus while its addition to each of the ALS mutant proteins (mutant + NLS) restored their nuclear localization. Furthermore, cytoplasmic mislocalized FUS associates with stress granule markers, a common feature of ALS associated proteins.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23474818","rdfs:label":"Mislocalization in cytoplasm"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/f7e64143-e97e-455d-aab2-55bf40f27f41","type":"EvidenceLine","dc:description":"FUS proteins carrying familial ALS (fALS) mutations are defective in DDR and DNA repair, and show a diminished interaction with HDAC1. Moreover, increased DNA damage was also observed in human ALS patients harboring FUS mutations. These findings suggest that an impaired DDR and DNA repair may contribute to the pathogenesis of neurodegenerative diseases linked to FUS mutations.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b0a9e2c9-9ebd-49cf-9ac9-a0297a3e634a","type":"FunctionalAlteration","dc:description":"To test the impact of fALS FUS mutations upon DDR and DNA repair, 4 fALS FUS mutants including R244C, R514S, H517Q and R521C (tagged with mCherry) were transfected into U2OS-GFP cell lines in which endogenous FUS expression was knocked down. Then I-SceI was expressed in these five cell lines to induce programmed DSBs, the percentage of GFP-positive cells 48 hours post-transfection was assessed using FACS. Compared to cells expressing FUS-WT, cells expressing fALS FUS mutants showed decreased percentage of GFP-positive cells, indicating deficient DSB repair. FUS-R244C and FUS-R514S presented the most severe deficiency in HR-mediated DSB repair, while the FUS-R521C cell line demonstrated a more modest deficiency, and FUS-H517Q had only a marginal defect. Further transfected the same stable cell lines with the NHEJ reporter construct to evaluate the DSB repair through the NHEJ mechanism and observed, similar to HR, the FUS-R514S and R521C mutants were also impaired in NHEJ-mediated DSB repair.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24036913","rdfs:label":"DDR and DNA repair"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Definitive","sequence":3499,"specifiedBy":"GeneValidityCriteria8","strengthScore":18,"subject":{"id":"https://genegraph.clinicalgenome.org/r/IqUxfmw1i4w","type":"GeneValidityProposition","disease":"obo:MONDO_0011951","gene":"hgnc:4010","modeOfInheritance":"obo:HP_0000006"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_b2e8f55b-371e-438f-8923-73ca9b7ec034-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}